



Targeted, efficient **STI*** screening and diagnostics

Sexually-transmitted infections

When certain diagnostic methods may be less sensitive, **how can you help ensure rapid, accurate detection?**

>1 billion

STIs are acquired every day worldwide.1

156 million

Estimated infections of *Trichomonas* vaginalis per year worldwide.²

>75%

of women experience at least one episode of vaginitis in their lifetime.³

STIs impose a substantial strain on national health systems. Because many STIs share common symptoms with patients often appearing asymptomatic altogether, they can be challenging to differentiate. Certain diagnostic methods such as wet preparation microscopy and antigen testing may be less sensitive in detecting and differentiating different STIs.^{4,5}

When left undetected, STIs can lead to severe patient complications including infertility, brain damage and possibly death.⁶

What if you could help ensure rapid STI detection by...



Simultaneously screening multiple STIs from a single patient sample?



Eliminating the need for a confirmatory test?



Providing same-day results for rapid clinical decisions?




Performing diagnostic tests with high sensitivity and specificity?

Harnessing the reliability of NAATs, STI screening and diagnosis on the **BD MAX™ System** combines innovation with rapid, accurate molecular testing. With our STI portfolio, your lab can benefit from:

- **Direct**, **simultaneous detection** of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* from a single patient sample.
- Dual targets for detection of chlamydia and gonorrhoeae, eliminating the need for a confirmatory test⁷
- Only **one vaginal swab specimen needed** to run BD CTGCTV2 or BD CTGC2 and BD Vaginal Panel
- The first semi-quantitative assay that holistically observes the microbiome to diagnose bacterial vaginosis

The right treatment starts with the right test



Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis can now be detected for both symptomatic and asymptomatic men and women with the **newly launched BD CTGCTV2 assay** on the BD MAX™ System.

You can also test for Mycoplasma genitallium on the BD MAX $^{\text{M}}$ System through an open system assay and extraction kit. For further information, **please contact your BD representative**.

Rapid, targeted STI testing on BD molecular platforms

Whatever your lab's testing throughput, the innovative BD molecular platforms respond to your workflow needs with efficiency and ease of use. An automated workflow **reduces manual tasks** to achieve rapid, reliable results and facilitates off-hour testing, helping to **offset molecular testing costs**.**8.9

The **BD MAX™ System,** a fully automated, molecular platform providing rapid results for low to mid-volume testing needs



The **BD COR™ System**, a fully automated platform for high-throughput screening of STIs



Discover our full assay portfolio and the BD MAX™ System



advancing-diagnostics.eu



advancingdiagnostics@bd.com

1. European Centre for Disease Prevention and Control. Developing a national strategy for prevention and control of sexually transmitted infections. Available at: https://www.ecdc.europa.eu/sites/default/files/ documents/strategies-to-control-STIs.pdf. 2. Centers for Disease Controland Prevention (CDC). Sexually Transmitted Infections: National Strategic Plan for the United States, 2021-2025. Accessed January 2022, at https://www.hhs.gov/sites/default/files/STI-National-Strategic-Plan-2021-2025.pdf 3. Workowski KA and Bolan GA. MMWR. Recomm Rep. 2021:64(RR-03):1-137. 4. Gaydos C, Klausner J, Deron M, Toskin I, Azzini A and Peeling R. Rapid and point-of-care tests for the diagnosis of urogenital gonococcal infections. Sex Transm Infect. 2017; 93(S4):S31-S35. 5. Guy R, Causer L, Klausner J, Unemo M, Toskin I, Azzini A and Peeling R. Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. Sex Transm Infect. 2017; 93(S4):S16-S21. 6. National Institute of Allergy and Infections Diseases. Sex Transm Infect. 2017; 93(S4):S16-S21. 6. National Institute of Allergy and Infections Diseases. Sexually Transmitted Diseases (STDs) Diagnosis. 2015. Available at: https://www.niaid.nih.gov/diseases-conditions/sexually-transmitted-diseases. Accessed January 2022. 7. Reference: Guidance for the detection of gonorrhoea in England: updated guidance 2021 Available at: https://www.niaid.nih.gov/diseases-conditions/sexually-transmitted-diseases. Accessed January 2022. 7. Reference: Guidance for the detection of gonorrhoea in England: updated guidance 2021 Available at: <a href="https://www.niaid.nih.gov/diseases-conditions/sex

^{**} When compared to culture or immunochromatographic antigen (IA)